Genenta Science (NASDAQ:GNTA) Rating Reiterated by HC Wainwright

Genenta Science (NASDAQ:GNTAGet Free Report)‘s stock had its “buy” rating restated by HC Wainwright in a research note issued to investors on Monday, Benzinga reports. They currently have a $25.00 price target on the stock.

Genenta Science Stock Down 8.2 %

GNTA opened at $3.22 on Monday. The stock’s 50 day moving average price is $3.56 and its 200-day moving average price is $4.27. Genenta Science has a one year low of $2.20 and a one year high of $6.81.

Genenta Science Company Profile

(Get Free Report)

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.

See Also

Receive News & Ratings for Genenta Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genenta Science and related companies with MarketBeat.com's FREE daily email newsletter.